Integrating NGS and CADD for the Identification of Medicinal Plant Compounds Targeting EGFR Mutants in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer remains a significant global contributor to cancer deaths, largely due to Epidermal Growth Factor Receptor (EGFR) mutation that drive disease progression and treatment resistance. This research seeks to uncover new therapeutic avenues for EGFR-mutant NSCLC by combining Next-Generation Sequencing (NGS) with Computer-Aided Drug Design (CADD). We'll leverage NGS to thoroughly examine genetic changes in tumor samples from patients, specifically looking at the LRTM mutation within the 8D76 EGFR structure. This analysis will help us identify biomarkers and new drug targets associated with these EGFR mutations. Building on this genetic data, we will apply CADD methods including molecular docking, virtual screening, and molecular dynamics simulations to screen a library of natural compounds derived from medicinal plants. The goal is to identify plant-based compounds with strong binding affinity and inhibitory activity against the mutant EGFR protein. This perspective accentuates the therapeutic capacity of natural products in oncology and the imperative of amalgamating indigenous knowledge with sophisticated biotechnological methodologies. Through the identification of efficacious lead compounds, this inquiry is poised to facilitate the evolution of more durable and precise interventions for individuals afflicted with non-small cell lung carcinoma (NSCLC) exhibiting refractory EGFR mutations. In doing so, it showcases a modern, holistic approach to drug discovery, harnessing both cutting-edge genomic analysis and the therapeutic potential of medicinal plants.